All In MedTech

Device Trial Radar · NCT01525134

Feasibility of a Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis

Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects

Last checked: Nov 20, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

504

Actual

Start

Jan 2011

Primary completion

Feb 2012

Study completion Apr 2012

Sponsor

Sponsor type
Research network
Collaborators
Makerere University
First posted
Feb 2, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the accuracy, diagnostic yield, operational performance, and time to diagnosis of a novel lateral-flow urine lipoarabinomannan (LAM) test in detecting tuberculosis in HIV-infected adults. A secondary study objective is to determine the accuracy, efficiency, costs, and cost-effectiveness of various combinations of Tuberculosis (TB) diagnostic tests, including the novel Xpert MTB/Rif test.

Conditions

  • Tuberculosis
  • Tuberculosis, Pulmonary
  • Tuberculosis, Miliary

Interventions

  • Alere "Determine" lateral-flow urine lipoarabinomannan assayDevice

    lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro. Manufacturer: Alere

  • Alere "Clearview" ELISA urine LAM assayDevice

    ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro. Manufacturer: Alere.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity of the lateral-flow urine LAM assay (LF-LAM)Time frame: One year
  2. Failure rate of the lateral-flow urine LAM assayTime frame: One year
  3. Inter-reader variability of the lateral-flow urine LAM assayTime frame: One year

1 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Infectious Diseases Institute, Makerere University

    Kampala, Uganda

  • Mulago National Referral Hospital

    Kampala, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.